Erucin
Based on 2 publication(s) in Google Scholar
Erucin (ERU) is an isothiocyanate particularly abundant in arugula. Erucin shows anticancer, neuroprotective, and anti-inflammatory activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.15%
- No. CAS: 4430-36-8
- Fòrmula: C6H11NS2
- Peso molecular:161.29
-
Almacenamiento:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Pyroptosis Compound Library
HY-L059
-
Neuroprotective Compound Library
HY-L070
-
Food Additive Library
HY-L093
-
Food-Sourced Compound Library
HY-L094
-
Human Metabolite Library
HY-L123
-
Cysteine Targeted Covalent Library
HY-L153
-
Cysteine Targeted Covalent Fragment Library
HY-L154
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Flavor Compound Library
HY-L202
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Flavors and Fragrances Compound Library
HY-L242
Publications Citing Use of MedChemExpress (MCE) Erucin
More
Actividad biológica
Erucin (ERU) (0-100 μM) releases H2S and inhibits cell viability in AsPC-1 cells in a concentration-dependent manner[1].
Erucin inhibits cell migration and altered the AsPC-1 cell cycle, reducing G0/G1 phase and increasing G2/M and S phases[1].
Erucin (30 μM, 72 h) induces AsPC-1 cell apoptosis and inhibits cell migration[1].
Erucin reduces levels of phosphorylated ERK1/2 in AsPC-1 cells[1].
Erucin (0-200 μM, 24 h) shows antiproliferative activity with an IC50 of 97.7 μM in A549 cells[2].
Erucin (0-50 μM, 24 h) induces the cleavage of PARP-1 at 50 μM, and increases p53 and p21 protein expression in A549 cells[2].
Erucin decreases LPS-induced production of NO, prostaglandin E2 (PGE2), TNF-α, IL-6 and IL-1β in RAW 264.7 cells[3].
Erucin decreases LPS-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in RAW 264.7 cells[3].
Erucin inhibits LPS-induced activation of NFκB Signaling in RAW 264.7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AsPC-1
-
Concentration:10, 30, and 100 μM
-
Incubation Time:72 h
-
Result:Showed a significant and concentration‐dependent reduction of cell viability.
-
Cell Line:AsPC-1
-
Concentration:30 μM
-
Incubation Time:72 h
-
Result:Significantly increased the number of total apoptotic cells (apoptotic dead cells and apoptotic live cells; vehicle: 17.7% ± 2.5 vs. Erucin: 28.7% ± 4.2).
-
Cell Line:AsPC-1
-
Concentration:30 μM
-
Incubation Time:72 h
-
Result:Showed a particular increase of cells number in the G2/M phase (36.6% vs. vehicle-treated cells in the G2/M phase: 24.0%) and in the S phase (18.1% vs. vehicle-treated cells in the S phase: 11.0%) and a consequent significant reduction of cells in the G0/G1 phase (35.1 vs. vehicle-treated cells in the G0/G1 phase: 59.5%.
-
Cell Line:A549
-
Concentration:0-200 µM
-
Incubation Time:24 h
-
Result:Showed antiproliferative effect with an IC50 of 97.7 µM.
-
Cell Line:A549
-
Concentration:0-50 µM
-
Incubation Time:24 h
-
Result:Induced the cleavage of PARP-1 at 50 µM. Increased p53 and p21 protein expression.
-
Cell Line:RAW 264.7
-
Concentration:0, 2.5, and 5 µM
-
Incubation Time:30 min
-
Result:Decreased the expression of iNOS and COX-2 induced by LPS. Suppressed the LPS-induced reduction in IκB-α. Suppressed NFκB DNA binding and transcriptional activity.
-
Cell Line:RAW 264.7
-
Concentration:0, 2.5, and 5 µM
-
Incubation Time:24 h
-
Result:Decreased LPS-induced TNF-α, IL-6 and IL-1β production.
Erucin (30 μmol/kg; i.p.; twice a week for 4 week) shows neuroprotective effects[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female ICR mice (4 weeks of age), TPA (12-O-tetradecanoylphorbol-13-acetate)-induced mouse ear edema model[3]
-
Dosage:0, 100, and 300 nM
-
Administration:Topically applied to the mouse ear 30 min prior to the topical application of TPA
-
Result:Significantly inhibited TPA-induced edema formation.
-
Animal Model:Male C57Bl/6 mice (9 weeks old, 25–30 g body weight)[4]
-
Dosage:30 μmol/kg
-
Administration:Intraperitoneal administration, twice a week, 4 weeks (Induce brain lesion by intrastriatal injection of 6-OHDA)
-
Result:Induced a partial recovery in the rotational behavior test. Upregulated the expression of TH. Counteract neuronal death and DNA fragmentation in 6-OHDA lesioned mice. increase total GSH and Nrf2 levels in 6-OHDA lesioned mice.
Chemical Information
-
No. CAS 4430-36-8
-
Appearance Liquid (Density: 1.03±0.1 g/cm3)
-
Peso molecular 161.29
-
Fòrmula C6H11NS2
-
Color Colorless to light yellow
-
SMILES
CSCCCCN=C=S
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Agric Food Chem
Characterization of Myrosinase-Mediated Glucosinolate Degradation Pathways in Lactiplantibacillus plantarum ZUST49. [Abstract]2025 Mar 26;73(12):7256-7269. PMID: 40062683 -
Solvente y solubilidad
DMSO : 100 mg/mL (620.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (416 KB)
- English - EN (416 KB)
- Français - FR (416 KB)
- Deutsch - DE (416 KB)
- Norwegian - NO (416 KB)
- Español - ES (416 KB)
- Swedish - SV (416 KB)
- Italian - IT (416 KB)
- Korean - KR (416 KB)
- Portuguese - PT (416 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Valentina Citi, et al. Anticancer properties of erucin, an H2 S-releasing isothiocyanate, on human pancreatic adenocarcinoma cells (AsPC-1). Phytother Res. 2019 Mar;33(3):845-855. [Content Brief]
[2]. A. Melchini, et al. Erucin, a new promising cancer chemopreventive agent from rocket salads, shows anti-proliferative activity on human lung carcinoma A549 cells. Food Chem Toxicol. 2009 Jul;47(7):1430-6. [Content Brief]
[3]. Han Jin Cho, et al. Erucin exerts anti-inflammatory properties in murine macrophages and mouse skin: possible mediation through the inhibition of NFκB signaling. Int J Mol Sci. 2013 Oct 15;14(10):20564-77. [Content Brief]
[4]. Fabiana Morroni, et al. Comparison of Adaptive Neuroprotective Mechanisms of Sulforaphane and its Interconversion Product Erucin in in Vitro and in Vivo Models of Parkinson's Disease. J Agric Food Chem. 2018 Jan 31;66(4):856-865. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.2000 mL | 31.0001 mL | 62.0001 mL | 155.0003 mL |
| 5 mM | 1.2400 mL | 6.2000 mL | 12.4000 mL | 31.0001 mL | |
| 10 mM | 0.6200 mL | 3.1000 mL | 6.2000 mL | 15.5000 mL | |
| 15 mM | 0.4133 mL | 2.0667 mL | 4.1333 mL | 10.3334 mL | |
| 20 mM | 0.3100 mL | 1.5500 mL | 3.1000 mL | 7.7500 mL | |
| 25 mM | 0.2480 mL | 1.2400 mL | 2.4800 mL | 6.2000 mL | |
| 30 mM | 0.2067 mL | 1.0333 mL | 2.0667 mL | 5.1667 mL | |
| 40 mM | 0.1550 mL | 0.7750 mL | 1.5500 mL | 3.8750 mL | |
| 50 mM | 0.1240 mL | 0.6200 mL | 1.2400 mL | 3.1000 mL | |
| 60 mM | 0.1033 mL | 0.5167 mL | 1.0333 mL | 2.5833 mL | |
| 80 mM | 0.0775 mL | 0.3875 mL | 0.7750 mL | 1.9375 mL | |
| 100 mM | 0.0620 mL | 0.3100 mL | 0.6200 mL | 1.5500 mL |
Erucin Related Classifications
HY-121323 Related Classifications
Powered by Bioz